CABA · Cabaletta Bio, Inc. · Financials
The latest filing states the doubt was alleviated.
“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $165.12M | $142.67M | $97.2M | $55.42M | $39.3M | $32.49M | $21.38M | $11.67M | $4.47M | |
| $28.51M | $29.57M | $27.94M | $19.24M | $14.84M | $13.82M | $12.46M | $7.01M | $1.73M | |
| $193.64M | $172.24M | $125.14M | $74.66M | $54.14M | $46.31M | $33.83M | $18.68M | $6.19M | |
| -$193.64M | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M | -$33.83M | -$18.68M | -$6.19M | |
| $2.22M | $2M | $748K | $0 | — | — | — | — | — | |
| $6.15M | $6.03M | $10.03M | $6.99M | $1.16M | $24K | $494K | $1.74M | $235K | |
| $0 | $0 | $0 | — | — | — | — | — | — | |
| -$189.51M | -$167.86M | -$115.86M | -$67.68M | -$52.98M | -$46.29M | -$33.34M | -$16.94M | -$12.2M | |
| — | — | — | — | — | — | -$33.34M | -$22.27M | -$12.2M | |
| -$189.53M | -$167.83M | -$115.9M | -$67.59M | -$53.02M | -$46.29M | -$33.33M | -$22.27M | — | |
| USD/shares | -$1.23 | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | — | — | — |
| USD/shares | -$1.23 | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | — | — | — |
| shares | — | — | — | 1.17M | 5.94M | — | — | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-09-30 | USD 13,684,000 | 10-Q filed 2026-11-05 |
| Current operating lease liabilities | 2026-09-30 | USD 4,250,000 | 10-Q filed 2026-11-05 |
| Noncurrent finance lease liabilities | 2026-09-30 | USD 4,738,000 | 10-Q filed 2026-11-05 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 502,000 | 10-Q filed 2026-11-05 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 335 similar-size Biotechnology companies (of 587 listed).